Based on meta-analysis data, PD-1 combinations seem superior compared to anti-PD-L1 combinations in NSCLC with conflicting data regarding toxicity, but mostly similar side effects (Brito et al. 2021; Pillai et al. 2018). Here, CD274 is linked to non-small cell lung carcinoma.